Annovis Bio Inc
$ 2.37
-1.25%
11 Feb - close price
- Market Cap 59,803,000 USD
- Current Price $ 2.37
- High / Low $ 2.46 / 2.29
- Stock P/E N/A
- Book Value 0.66
- EPS -2.10
- Next Earning Report 2026-03-20
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.12 %
- ROE -3.65 %
- 52 Week High 5.50
- 52 Week Low 1.11
About
Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.
Analyst Target Price
$13.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-12 | 2025-05-08 | 2025-03-27 | 2024-11-06 | 2024-08-14 | 2024-05-10 | 2024-03-29 | 2023-11-08 | 2023-08-14 | 2023-05-10 | 2023-03-01 |
| Reported EPS | -0.37 | -0.32 | -0.32 | -0.43 | -0.97 | -0.32 | -0.72 | -2.24 | -1.63 | -1.07 | -1.19 | -1.05 |
| Estimated EPS | -0.305 | -0.4031 | -0.8 | -0.2 | -0.53 | -0.63 | -0.8 | -1.3 | -1.09 | -1.14 | -0.33 | -1.05 |
| Surprise | -0.065 | 0.0831 | 0.48 | -0.23 | -0.44 | 0.31 | 0.08 | -0.94 | -0.54 | 0.07 | -0.86 | 0 |
| Surprise Percentage | -21.3115% | 20.6152% | 60% | -115% | -83.0189% | 49.2063% | 10% | -72.3077% | -49.5413% | 6.1404% | -260.6061% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-20 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ANVS
2026-01-28 21:59:51
Annovis Bio (ANVS) held a public webinar on January 28, 2026, accompanied by a presentation, as a formal communication to the market. Despite this, the announcement did not disclose any new operational or strategic details. An analyst currently rates ANVS stock as a "Hold" with a $3.00 price target, and TipRanks' AI Analyst, Spark, rates it Neutral due to weak financial performance and dilution risk from a recent equity raise.
2026-01-28 21:59:51
Annovis Bio, Inc. has announced significant advancements in their Alzheimer's and Parkinson's clinical trials, with 40% enrollment in the Phase 3 Alzheimer's trial and the start of patient screening for the Parkinson's Open Label Extension study. The company is also discussing new Parkinson's disease dementia study endpoints with the FDA. Buntanetap, their drug candidate, is showing promise in cognitive improvement and potential disease-modifying effects for both conditions.
2026-01-28 10:59:52
Annovis Bio is focusing investor attention on its clinical development through an upcoming webinar, moving past short-term stock volatility. The company is advancing Phase 3 trials for Alzheimer's and Parkinson's diseases, with a significant Type-C meeting with the FDA scheduled for January 2026 to discuss Parkinson's disease dementia. These events and ongoing clinical readouts are expected to define the company's strategic direction and future valuation.
2026-01-21 07:57:20
Annovis Bio, Inc. (NYSE:ANVS) has received an average "Hold" recommendation from five analysts, with a 12-month target price of $13.50. Despite this, significant insider buying, including purchases by a director and the CEO totaling over $2.66 million, indicates internal confidence. The clinical-stage biotechnology company, focused on neurodegenerative disorders, currently trades around $2.80 with a market capitalization of $74 million.
2026-01-09 01:57:28
The article highlights key neurology clinical trial readouts anticipated in early 2026, covering a range of conditions from Alzheimer's and Parkinson's to multiple sclerosis and multiple system atrophy. These trials evaluate novel therapies, including oral treatments, muscarinic receptor agonists, and BTK inhibitors, with potential to significantly impact future treatment paradigms and clinical decision-making across various neurological disorders. The studies focus on primary endpoints such as cognitive decline, motor complications, relapse rates, and quality of life measures, aiming to bring new therapeutic approaches to patients.
2026-01-07 14:27:11
Annovis Bio (ANVS) stock has reached a new 52-week low, trading at $4.05 per share. This decline highlights significant market challenges facing the company, indicating investor concerns or broader industry pressures.
